JP2024514528A - 線維芽細胞活性化タンパク質アルファおよび／または前立腺特異的膜抗原を標的とするヘテロ二価およびホモ二価薬剤 - Google Patents

線維芽細胞活性化タンパク質アルファおよび／または前立腺特異的膜抗原を標的とするヘテロ二価およびホモ二価薬剤 Download PDF

Info

Publication number
JP2024514528A
JP2024514528A JP2023560919A JP2023560919A JP2024514528A JP 2024514528 A JP2024514528 A JP 2024514528A JP 2023560919 A JP2023560919 A JP 2023560919A JP 2023560919 A JP2023560919 A JP 2023560919A JP 2024514528 A JP2024514528 A JP 2024514528A
Authority
JP
Japan
Prior art keywords
group
compound
alkyl
fap
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024514528A5 (enExample
Inventor
バネルジー レイ サンギータ
ボイナパリー スリカンス
ギルバート ポンパー マーティン
ホルティ アンドリュー
ダス ディーパンカー
ミン イル
キャロル ローレンス
チャ ヒョジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of JP2024514528A publication Critical patent/JP2024514528A/ja
Publication of JP2024514528A5 publication Critical patent/JP2024514528A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/221—Echographic preparations; Ultrasonic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acoustics & Sound (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023560919A 2021-04-02 2022-04-04 線維芽細胞活性化タンパク質アルファおよび／または前立腺特異的膜抗原を標的とするヘテロ二価およびホモ二価薬剤 Pending JP2024514528A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163170035P 2021-04-02 2021-04-02
US63/170,035 2021-04-02
PCT/US2022/023374 WO2022212958A1 (en) 2021-04-02 2022-04-04 Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen

Publications (2)

Publication Number Publication Date
JP2024514528A true JP2024514528A (ja) 2024-04-02
JP2024514528A5 JP2024514528A5 (enExample) 2025-04-14

Family

ID=83459940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560919A Pending JP2024514528A (ja) 2021-04-02 2022-04-04 線維芽細胞活性化タンパク質アルファおよび／または前立腺特異的膜抗原を標的とするヘテロ二価およびホモ二価薬剤

Country Status (11)

Country Link
US (1) US20240382629A1 (enExample)
EP (1) EP4313049A4 (enExample)
JP (1) JP2024514528A (enExample)
KR (1) KR20230165818A (enExample)
CN (1) CN117255685A (enExample)
AU (1) AU2022252419A1 (enExample)
BR (1) BR112023020123A2 (enExample)
CA (1) CA3214070A1 (enExample)
IL (1) IL307405A (enExample)
MX (2) MX2023011599A (enExample)
WO (1) WO2022212958A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
IL319722A (en) 2022-09-23 2025-05-01 Nuclidium Ag High purity radionuclides and their diagnostic and medical uses
WO2024078592A1 (zh) * 2022-10-14 2024-04-18 无锡诺宇医药科技有限公司 靶向成纤维细胞活化蛋白的药物及其应用
CN118852122A (zh) * 2023-04-27 2024-10-29 中国科学院上海药物研究所 一种fap抑制剂和靶向fap核素探针及其应用
US12440585B2 (en) * 2023-09-12 2025-10-14 Curadel Surgical Innovations, Inc. Zwitterionic metal chelators
WO2025087229A1 (zh) * 2023-10-27 2025-05-01 四川科伦博泰生物医药股份有限公司 一类喹啉结构的配体化合物及其放射性或非放射性标记物以及应用
KR20250062978A (ko) * 2023-10-31 2025-05-08 서울대학교병원 신규한 전립선 특이적 막 항원 리간드 및 이의 용도
WO2025119908A1 (en) * 2023-12-06 2025-06-12 Bracco Imaging Spa Psma-targeting fluorescent probes
WO2025163029A1 (en) 2024-01-31 2025-08-07 Bracco Imaging Spa Psma-targeting bimodal and heterobivalent fluorescent agents
CN117700485B (zh) * 2024-02-04 2024-04-16 山东大学 一种同时靶向psma和fap的化合物及其制备方法与应用
WO2025167951A1 (zh) * 2024-02-07 2025-08-14 苏州博锐创合医药有限公司 一种成纤维细胞活化蛋白抑制剂
US12086990B1 (en) * 2024-04-23 2024-09-10 MultiFunctional Imaging LLC Systems and methods for simultaneous imaging of multiple positron emission tomography (PET) tracers
CN118271393B (zh) * 2024-05-31 2024-09-03 中国药科大学 一种靶向fap的二聚化合物及其探针和应用
CN119080743B (zh) * 2024-08-30 2026-01-06 北京师范大学 靶向psma和fap的双重靶向化合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500373A (ja) * 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013107820A1 (en) * 2012-01-17 2013-07-25 Universiteit Antwerpen Novel fap inhibitors
PH12020551205A1 (en) * 2018-02-06 2021-04-19 Univ Heidelberg Fap inhibitors
CN112088169A (zh) * 2018-03-12 2020-12-15 纪念斯隆凯特琳癌症中心 双特异性结合剂及其用途
KR20210116437A (ko) * 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
CN113292538A (zh) * 2021-05-10 2021-08-24 北京肿瘤医院(北京大学肿瘤医院) 靶向肿瘤相关成纤维细胞激活蛋白的化合物及其制备方法和应用与靶向fap的肿瘤显影剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500373A (ja) * 2017-10-23 2021-01-07 ザ・ジョンズ・ホプキンス・ユニバーシティ 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM., vol. 55, JPN6026024147, January 2022 (2022-01-01), pages 1 - 8, ISSN: 0005885675 *
J. LABELLED COMPD. RADIOPHARM., vol. 64(8), JPN6026024148, May 2021 (2021-05-01), pages 346 - 352, ISSN: 0005885674 *
MOL. IMAGING BIOL., vol. 23(5), JPN6026024146, March 2021 (2021-03-01), pages 686 - 696, ISSN: 0005885673 *
MOL. PHARM., vol. 18(11), JPN6026024145, September 2021 (2021-09-01), pages 4179 - 4187, ISSN: 0005885672 *

Also Published As

Publication number Publication date
BR112023020123A2 (pt) 2024-01-23
CA3214070A1 (en) 2022-10-06
EP4313049A4 (en) 2026-01-21
KR20230165818A (ko) 2023-12-05
CN117255685A (zh) 2023-12-19
MX2023011599A (es) 2024-02-02
EP4313049A1 (en) 2024-02-07
IL307405A (en) 2023-12-01
MX2026000948A (es) 2026-03-02
US20240382629A1 (en) 2024-11-21
AU2022252419A1 (en) 2023-10-19
WO2022212958A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
US20240382629A1 (en) Heterobivalent and homobivalent agents targeting fibroblast activation protein alpha and/or prostate-specific membrane antigen
US20250186628A1 (en) Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha)
JP2025013486A (ja) 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法
CN113166054A (zh) 成像剂
CN117603148A (zh) 双官能螯合物的药代动力学增强及其用途
TW201034691A (en) Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof
Boss et al. Comparative studies of three pairs of α-and γ-conjugated folic acid derivatives labeled with fluorine-18
CN110366432A (zh) 基于pd-l1表达的肿瘤和免疫细胞成像
JP7324763B2 (ja) 分子イメージングのための二重標識プローブ及びその使用
US20220054659A1 (en) Psma-targeted pamam dendrimers for specific delivery of imaging, contrast and therapeutic agents
CA3243418A1 (en) COMPOUNDS AND RADIOLIGANDS TO TARGET THE NEUROTENSIN RECEPTOR AND RELATED USES
TW202508616A (zh) Fap靶向環肽及其軛合物
JP2025536589A (ja) 標的化送達用の炭酸脱水酵素ｉｘリガンド
HK40094491A (en) Compound and pharmaceutical composition for targeting fibroblast-activation protein-alpha and use thereof
WO2025088200A2 (en) Acid phosphatase 3 ligands for targeted delivery applications
JP2025530298A (ja) 腫瘍細胞の検出のための放射性核種組成物及びその使用方法
TW202535356A (zh) 神經肽y1受體(npy1r)靶向治療劑及其用途
HK40114422A (en) Compounds and radioligands for targeting neurotensin receptor and uses thereof
HK40084697A (en) Fgfr3-targeted radioimmunoconjugates and uses thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260616